Pars Isotope’s Active Participation in the 31st National Nuclear Conference

During the 31st National Nuclear Conference of Iran, held from May 13 to 15, 2025, in Mashhad, Pars Isotope Company had an effective presence in this scientific event by presenting two significant achievements in the field of FAPI radiopharmaceuticals.

On the first day of the conference, Pars Isotope organized a specialized panel focusing on FAPI radiopharmaceuticals. The session began with an introduction to the FAPI molecule from both chemical structure and biological properties perspectives. Subsequently, Pars Isotope’s Gallium-FAPI and Lutetium-FAPI radiopharmaceuticals were presented, with detailed discussions on their performance in targeted diagnosis and treatment of specific cancer types. The session concluded with a presentation of medical imaging results and therapeutic outcomes from patients who had shown significant improvement after using these radiopharmaceuticals.

During this event, Pars Isotope unveiled the FAPI radiopharmaceutical kit. This kit, as an independent product, enables the preparation of Technetium-FAPI radiopharmaceutical, which can be used with SPECT imaging devices. The introduction of this product is considered an effective step toward developing cost-effective and accessible methods for accurate diagnosis of malignant diseases.

The active and scientific participation of Pars Isotope in this conference demonstrates the company’s key role in developing advanced radiopharmaceutical technologies in Iran, and enhances the country’s position in nuclear medicine at both regional and international levels.